Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 8/2021

01-08-2021 | Magnetic Resonance Imaging | Magnetic Resonance

Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging

Authors: Dow-Mu Koh, Ahmed Ba-Ssalamah, Giuseppe Brancatelli, Ghaneh Fananapazir, M. Isabel Fiel, Satoshi Goshima, Sheng-Hong Ju, Nikolaos Kartalis, Masatoshi Kudo, Jeong Min Lee, Takamichi Murakami, Max Seidensticker, Claude B. Sirlin, Cher Heng Tan, Jin Wang, Jeong Hee Yoon, Mengsu Zeng, Jian Zhou, Bachir Taouli

Published in: European Radiology | Issue 8/2021

Login to get access

Abstract

Objectives

The 9th International Forum for Liver Magnetic Resonance Imaging (MRI) was held in Singapore in September 2019, bringing together radiologists and allied specialists to discuss the latest developments in and formulate consensus statements for liver MRI, including the applications of gadoxetic acid–enhanced imaging.

Methods

As at previous Liver Forums, the meeting was held over 2 days. Presentations by the faculty on days 1 and 2 and breakout group discussions on day 1 were followed by delegate voting on consensus statements presented on day 2. Presentations and discussions centered on two main meeting themes relating to the use of gadoxetic acid–enhanced MRI in primary liver cancer and metastatic liver disease.

Results and conclusions

Gadoxetic acid–enhanced MRI offers the ability to monitor response to systemic therapy and to assist in pre-surgical/pre-interventional planning in liver metastases. In hepatocellular carcinoma, gadoxetic acid–enhanced MRI provides precise staging information for accurate treatment decision-making and follow-up post therapy. Gadoxetic acid–enhanced MRI also has potential, currently investigational, indications for the functional assessment of the liver and the biliary system. Additional voting sessions at the Liver Forum debated the role of multidisciplinary care in the management of patients with liver disease, evidence to support the use of abbreviated imaging protocols, and the importance of standardizing nomenclature in international guidelines in order to increase the sharing of scientific data and improve the communication between centers.

Key Points

• Gadoxetic acid–enhanced MRI is the preferred imaging method for pre-surgical or pre-interventional planning for liver metastases after systemic therapy.
• Gadoxetic acid–enhanced MRI provides accurate staging of HCC before and after treatment with locoregional/biologic therapies.
• Abbreviated protocols for gadoxetic acid–enhanced MRI offer potential time and cost savings, but more evidence is necessary. The use of gadoxetic acid–enhanced MRI for the assessment of liver and biliary function is under active investigation.
Appendix
Available only for authorised users
Literature
1.
Pillay B, Wootten AC, Crowe H et al (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev 42:56–72PubMed
2.
3.
4.
5.
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750PubMed
6.
7.
Chang TT, Sawhney R, Monto A et al (2008) Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 10:405–411
8.
Yopp AC, Mansour JC, Beg MS et al (2014) Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 21:1287–1295PubMed
9.
Serper M, Taddei TH, Mehta R et al (2017) Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 152:1954–1964PubMed
10.
Sinn DH, Choi GS, Park HC et al (2019) Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One 14:e0210730PubMedPubMedCentral
11.
Charriere B, Muscari F, Maulat C et al (2017) Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings. J Surg Oncol 115:330–336PubMed
12.
Engstrand J, Kartalis N, Stromberg C et al (2017) The impact of a hepatobiliary multidisciplinary team assessment in patients with colorectal cancer liver metastases: a population-based study. Oncologist 22:1067–1074PubMedPubMedCentral
13.
Adam R, de Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:729–741PubMed
14.
Zech CJ, Ba-Ssalamah A, Berg T et al (2020) Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 30:370–382PubMed
15.
Marks RM, Ryan A, Heba ER et al (2015) Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol 204:527–535PubMed
16.
Tillman BG, Gorman JD, Hru JM et al (2018) Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol 73:485–493PubMed
17.
Besa C, Lewis S, Pandharipande PV et al (2017) Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY) 42:179–190
18.
Canellas R, Patel MJ, Agarwal S, Sahani DV (2019) Lesion detection performance of an abbreviated gadoxetic acid-enhanced MRI protocol for colorectal liver metastasis surveillance. Eur Radiol 29:5852–5860PubMed
19.
Min JH, Kim YK, Choi SY et al (2018) Detection of recurrent hepatocellular carcinoma after surgical resection: non-contrast liver MR imaging with diffusion-weighted imaging versus gadoxetic acid-enhanced MR imaging. Br J Radiol 91:20180177PubMedPubMedCentral
20.
Hwang JA, Kim YK, Min JH, Song KD, Sohn I, Ahn HS (2019) Non-contrast liver MRI as an alternative to gadoxetic acid-enhanced MRI for liver metastasis from colorectal cancer. Acta Radiol 60:441–450PubMed
21.
Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM (2016) Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford) 18:485–493
22.
Mitchell D, Puckett Y, Nguyen QN (2019) Literature review of current management of colorectal liver metastasis. Cureus 11:e3940PubMedPubMedCentral
23.
Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215PubMed
24.
Bridgewater JA, Pugh SA, Maishman T et al (2020) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:398–411PubMedPubMedCentral
25.
Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572PubMedPubMedCentral
26.
Kuhl CK, Alparslan Y, Schmoee J et al (2019) Validity of RECIST Version 1.1 for response assessment in metastatic cancer: a prospective, multireader study. Radiology 290:349–356PubMed
27.
28.
Murata S, Matsushima S, Sato Y et al (2018) Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging. Abdom Radiol (NY) 43:3301–3306
29.
30.
Hosseini-Nik H, Fischer SE, Moulton CA et al (2016) Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy. Abdom Radiol (NY) 41:231–238
31.
Jhaveri KS, Fischer SE, Hosseini-Nik H et al (2017) Prospective comparison of gadoxetic acid-enhanced liver MRI and contrast-enhanced CT with histopathological correlation for preoperative detection of colorectal liver metastases following chemotherapy and potential impact on surgical plan. HPB (Oxford) 19:992–1000
32.
Tsilimigras DI, Ntanasis-Stathopoulos I, Paredes AZ et al (2019) Disappearing liver metastases: a systematic review of the current evidence. Surg Oncol 29:7–13PubMed
33.
van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA (2010) Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 14:1691–1700PubMed
34.
Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945PubMed
35.
Park MJ, Hong N, Han K et al (2017) Use of imaging to predict complete response of colorectal liver metastases after chemotherapy: MR imaging versus CT imaging. Radiology 284:423–431PubMed
36.
Owen JW, Fowler KJ, Doyle MB, Saad NE, Linehan DC, Chapman WC (2016) Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB (Oxford) 18:296–303
37.
Kim SS, Song KD, Kim YK et al (2017) Disappearing or residual tiny (</=5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: is local treatment required? Eur Radiol 27:3088–3096PubMed
38.
Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124PubMed
39.
Shin NY, Kim MJ, Lim JS et al (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22:864–871PubMed
40.
Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931PubMed
41.
Kim TH, Kim SY, Tang A, Lee JM (2019) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 25:245–263PubMedPubMedCentral
42.
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
43.
Kokudo N, Takemura N, Hasegawa K et al (2019) Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49:1109–1113PubMed
44.
Korean Liver Cancer Association (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice guidelines for the management of hepatocellular carcinoma. Gut Liver 13:227–299
45.
Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370PubMed
46.
Rao SX, Wang J, Wang J et al (2019) Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: gadoxetic acid disodium. J Dig Dis 20:54–61PubMed
47.
Zhou J, Sun HC, Wang Z et al (2018) Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer 7:235–260PubMedPubMedCentral
48.
Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12
49.
Corwin MT, Lee AY, Fananapazir G, Loehfelm TW, Sarkar S, Sirlin CB (2018) Nonstandardized terminology to describe focal liver lesions in patients at risk for hepatocellular carcinoma: implications regarding clinical communication. AJR Am J Roentgenol 210:85–90PubMed
50.
Elsayes KM, Kielar AZ, Chernyak V et al (2019) LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 6:49–69PubMedPubMedCentral
51.
Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L (2016) Hepatocellular carcinoma: therapeutic guidelines and medical treatment. Liver Cancer 6:16–26PubMedPubMedCentral
52.
Ikeda M, Han K-W, Miyayama S et al (2019) Changing paradigm of treatment strategy for intermediate stage HCC: APPLE Expert Consensus. Liver Cancer 8(Suppl 1):13
53.
Choi SH, Byun JH, Kwon HJ et al (2015) The usefulness of gadoxetic acid-enhanced dynamic magnetic resonance imaging in hepatocellular carcinoma: toward improved staging. Ann Surg Oncol 22:819–825PubMed
54.
55.
Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI (2015) Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 274:149–160PubMed
56.
Lee DH, Lee JM, Yu MH et al (2019) Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. Eur Radiol 29:3122–3131PubMed
57.
Renzulli M, Biselli M, Brocchi S et al (2018) New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 67:1674–1682PubMed
58.
Ricke J, Bartolozzi C, Berg T, et al The impact of gadoxetic acid enhanced hepato-biliary MRI on treatment decisions in hepatocellular carcinoma: the SORAMIC trial diagnostic cohort. Presented at: Radiological Society of North America, Chicago, IL
59.
Liu Q, Li A, Sun S, Luo R, Chen F (2014) The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation? J BUON 19:398–405PubMed
60.
Dimitroulis D, Damaskos C, Valsami S et al (2017) From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol 23:5282–5294PubMedPubMedCentral
61.
Bargellini I, Bozzi E, Campani D et al (2013) Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 82:e212–e218PubMed
62.
Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623PubMed
63.
Gillmore R, Stuart S, Kirkwood A et al (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55:1309–1316PubMed
64.
Riaz A, Memon K, Miller FH et al (2011) Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 54:695–704PubMed
65.
Yeo DM, Choi JI, Lee YJ, Park MY, Chun HJ, Lee HG (2014) Comparison of RECIST, mRECIST, and Choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. J Comput Assist Tomogr 38:391–397PubMed
66.
Gordic S, Corcuera-Solano I, Stueck A et al (2017) Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology. J Hepatol 67:1213–1221PubMed
67.
Rimola J, Forner A, Sapena V et al (2020) Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 30:186–194PubMed
68.
Joo I, Kim HC, Kim GM, Paeng JC (2018) Imaging evaluation following (90) Y radioembolization of liver tumors: what radiologists should know. Korean J Radiol 19:209–222PubMedPubMedCentral
69.
Schelhorn J, Best J, Reinboldt MP et al (2015) Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol. J Vasc Interv Radiol 26:972–979PubMed
70.
Boas FE, Do B, Louie JD et al (2015) Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 26:69–73PubMed
71.
Cozzi L, Dinapoli N, Fogliata A et al (2017) Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 17:829PubMedPubMedCentral
72.
Saini A, Breen I, Pershad Y et al (2018) Radiogenomics and radiomics in liver cancers. Diagnostics (Basel) 9:4
73.
Taouli B, Hoshida Y, Kakite S et al (2017) Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol 27:4472–4481PubMedPubMedCentral
74.
Yang L, Gu D, Wei J et al (2018) Radiomics nomogram for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Liver Cancer 8:373–386PubMedPubMedCentral
75.
Ba-Ssalamah A, Bastati N, Wibmer A et al (2017) Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging 45:646–659PubMed
76.
Feier D, Balassy C, Bastati N, Fragner R, Wrba F, Ba-Ssalamah A (2016) The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach. Eur Radiol 26:539–546PubMed
77.
Bastati N, Beer L, Mandorfer M et al (2020) Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 294:98–107PubMed
78.
Beer L, Mandorfer M, Bastati N et al (2019) Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 29:6600–6610PubMedPubMedCentral
79.
Asenbaum U, Ba-Ssalamah A, Mandorfer M et al (2017) Effects of portal hypertension on gadoxetic acid-enhanced liver magnetic resonance: diagnostic and prognostic implications. Invest Radiol 52:462–469PubMed
80.
Sandrasegaran K, Cui E, Elkady R et al (2018) Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis? Eur Radiol 28:4215–4224PubMed
81.
Asenbaum U, Kaczirek K, Ba-Ssalamah A et al (2018) Post-hepatectomy liver failure after major hepatic surgery: not only size matters. Eur Radiol 28:4748–4756PubMedPubMedCentral
82.
Wibmer A, Aliya Q, Steininger R et al (2012) Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Invest Radiol 47:353–358PubMed
83.
Petrillo M, Ierardi AM, Tofanelli L et al (2019) Gd-EOB-DTP-enhanced MRC in the preoperative percutaneous management of intra and extrahepatic biliary leakages: does it matter? Gland Surg 8:174–183PubMedPubMedCentral
84.
Cieszanowski A, Stadnik A, Lezak A et al (2013) Detection of active bile leak with Gd-EOB-DTPA enhanced MR cholangiography: comparison of 20-25 min delayed and 60-180 min delayed images. Eur J Radiol 82:2176–2182PubMed
85.
Wong YC, Wang LJ, Wu CH et al (2018) Detection and characterization of traumatic bile leaks using Gd-EOB-DTPA enhanced magnetic resonance cholangiography. Sci Rep 8:14612PubMedPubMedCentral
86.
Lee JH, Kim B, Kim HJ, Kim BW, Wang HJ, Kim JK (2018) High spatial resolution navigated 3D T1-weighted hepatobiliary MR cholangiography using Gd-EOB-DTPA for evaluation of biliary anatomy in living liver donors. Abdom Radiol (NY) 43:1703–1712
87.
Kang HJ, Lee JM, Ahn SJ et al (2019) Clinical feasibility of gadoxetic acid-enhanced isotropic high-resolution 3-dimensional magnetic resonance cholangiography using an iterative denoising algorithm for evaluation of the biliary anatomy of living liver donors. Invest Radiol 54:103–109PubMed
88.
Poetter-Lang S, Staufer K, Baltzer P et al (2019) The efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: a clinical observational cohort study. Eur Radiol 29:1048–1058PubMed
Metadata
Title
Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging
Authors
Dow-Mu Koh
Ahmed Ba-Ssalamah
Giuseppe Brancatelli
Ghaneh Fananapazir
M. Isabel Fiel
Satoshi Goshima
Sheng-Hong Ju
Nikolaos Kartalis
Masatoshi Kudo
Jeong Min Lee
Takamichi Murakami
Max Seidensticker
Claude B. Sirlin
Cher Heng Tan
Jin Wang
Jeong Hee Yoon
Mengsu Zeng
Jian Zhou
Bachir Taouli
Publication date
01-08-2021
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 8/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07637-4

Other articles of this Issue 8/2021

European Radiology 8/2021 Go to the issue

Musculoskeletal

Evidence-based use of clinical examination, ultrasonography, and MRI for diagnosing ulnar collateral ligament tears of the metacarpophalangeal joint of the thumb: systematic review and meta-analysis

Cardiac

Prognostic value of stress cardiovascular magnetic resonance in asymptomatic patients without known coronary artery disease

Computed Tomography

Computed tomographic angiography may be used for assessing the dilatation of the anterior choroidal and posterior communicating arteries in patients with moyamoya syndrome

Neuro

Short diameter may be a useful simple indicator of the tumor response in skull base meningiomas after conventionally fractionated stereotactic radiotherapy

Magnetic Resonance

Whole-tumor texture model based on diffusion kurtosis imaging for assessing cervical cancer: a preliminary study

Magnetic Resonance

Evaluation of microvascular permeability of skeletal muscle and texture analysis based on DCE-MRI in alloxan-induced diabetic rabbits